At the molecular level, CLL is characterized by the clonal expansion of neoplastic CD5+, CD19+, and CD23+ B-cells [3], which can elicit a wide range of heterogeneous clinical features from indolent to highly aggressive disease manifestations in CLL patients [4]. Here, FCER2 is linked to B-cell chronic lymphocytic leukemia.